Oncotype DX Breast Recurrence Score

For women diagnosed with early-stage, estrogen-receptor-positive, HER2-negative invasive breast cancer, Exact Sciences offers the Oncotype DX Breast Recurrence Score® test to help patients and their doctors understand what treatment options are right for them, including if they are likely to benefit from chemotherapy.

The Breast Recurrence Score® assay is one of the most extensively studied genomic tests available for breast cancer patients today, with prospective clinical trials and outcome data gathered from more than 100,000 patients in more than 150 publications, providing the highest level of evidence supporting the test’s clinical utility.1



The Breast Recurrence Score test is the only validated genomic test for breast cancer, which provides two key answers for both lymph node-negative and node-positive early-stage breast cancer patients:

  • The test predicts whether a woman will benefit from chemotherapy.
  • It also provides a percent likelihood of the cancer returning after appropriate hormone therapy is taken.

The Oncotype DX Breast Recurrence Score test is incorporated in all major breast cancer treatment guidelines for both prognosis and chemotherapy benefit, including the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the St. Gallen Consensus panel, the National Institute for Health Care Excellence, the European Society for Medical Oncology and the German Association of Gynecological Oncology.


1Exact Sciences Estimates